Investigation of the effect of intravitreal bevacizumab treatment on left heart function using speckle tracking echocardiography

Basit Öğe Kaydı
dc.contributor.authorŞahinbaş, Mehmet
dc.contributor.authorÇerik, İdris Buğra
dc.contributor.authorYalınbaş Yeter, Duygu
dc.date.accessioned2024-10-26T17:51:40Z
dc.date.available2024-10-26T17:51:40Z
dc.date.issued2024
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractIntroduction and objectives: Vascular endothelial growth factor (VEGF) inhibitors are widely used in oncology and ophthalmology. Although these agents have been shown to increase the risk of cardiovascular events in systemic use, the effect of local applications is unclear. In our study, we aimed to investigate the effects of anti-VEGF agents on left heart functions after intravitreal injection using speckle tracking echocardiography. Methods: In this prospectively designed study, 44 patients who were going to start intravitreal anti-VEGF treatment were included in the study. Patients were evaluated with speckle tracking echocardiography before the first anti-VEGF administration and at three months of anti-VEGF treatment. Results: Global longitudinal strain (GLS) values at three months were lower in the patients who participated in the study and this was statistically significant (?18.77±2.17, ?18.60±2.01, p=0.001). Also, there was a statistically significant decrease in the mean values of GLS (GLS4CH) obtained from apical four space image, GLS (GLSAPLAX) obtained from apical long axis image and GLS (GLS2CH) obtained from apical 2 space image at month 0 and month 3 (?19.08±2.39, ?18.93±2.26, p=0.004; ?18.81±2.29, ?18.60±2.12, p=0.001; ?18.44±2.31, ?18.27±2.12, p=0.013, respectively). Conclusion: The slight decrease in GLS in our study suggests that the use of intravitreal anti-VEGF agents may have cardiac effects. © 2024 Sociedade Portuguesa de Cardiologia
dc.identifier.doi10.1016/j.repc.2024.07.006
dc.identifier.issn0870-2551
dc.identifier.scopus2-s2.0-85203660294
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.repc.2024.07.006
dc.identifier.urihttps://hdl.handle.net/20.500.12418/26375
dc.identifier.wosWOS:001424247000001
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSociedade Portuguesa de Cardiologia
dc.relation.ispartofRevista Portuguesa de Cardiologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAnti-VEGF; Bevacizumab; Cardiovascular risk; Speckle tracking echocardiography
dc.titleInvestigation of the effect of intravitreal bevacizumab treatment on left heart function using speckle tracking echocardiography
dc.title.alternativeInvestigação do efeito do tratamento intravítreo com bevacizumabe na função cardíaca esquerda por ecocardiografia com speckle tracking
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu